帕妥珠单抗
生物仿制药
曲妥珠单抗
医学
多西紫杉醇
肿瘤科
内科学
乳腺癌
随机对照试验
癌症
作者
Wen‐Jia Zuo,Zhonghua Wang,Jun Qian,Xiaopeng Ma,Zhaofeng Niu,Jianghua Ou,Qinguo Mo,Jing Sun,Xinzheng Li,Qitang Wang,Yongzhong Yao,Guohua Yu,Hongsheng Li,Dedian Chen,Hao Zhang,Cuizhi Geng,Guangdong Qiao,Mengmeng Zhao,Baihui Zhang,Xiaoyan Kang
标识
DOI:10.1038/s41416-024-02751-2
摘要
BACKGROUND: This randomized, parallel-controlled, double-blinded, phase III equivalence study evaluated the equivalence of a proposed pertuzumab biosimilar QL1209 to the pertuzumab (Perjeta®) each with trastuzumab and docetaxel in neoadjuvant treatment of early or locally advanced breast cancer patients with HER2-positive, ER/PR-negative. METHODS: Eligible patients were randomly (1:1) assigned to receive 4 cycles of neoadjuvant QL1209 or pertuzumab each with trastuzumab and docetaxel, and adjuvant treatment. The primary endpoint was total pathologic complete response (tpCR), with equivalence margins of 0.76 to 1.32. RESULTS: Among the 585 patients enrolled, 257 and 259 patients were assigned to the QL1209 and pertuzumab groups, respectively. The tpCR rates were comparable in the QL1209 (109/255, 42.75%; 90% CI 37.65 to 47.84) and pertuzumab (117/259, 45.17%; 90% CI 40.09 to 50.26) groups. The tpCR risk ratio was 0.95 (90% CI, 0.80 to 1.11), and the 90% CI fell within the predefined equivalence margin. The most common grade ≥3 treatment-related adverse event was decreased neutrophil count (10. 9% vs. 12.7%) in the QL1209 and pertuzumab groups. CONCLUSIONS: QL1209 demonstrated equivalent efficacy and comparable safety profile to the reference pertuzumab in neoadjuvant treatment of HER2-positive, ER/PR-negative, early, or locally advanced breast cancer. TRIAL REGISTRATION: Chinadrugtrials.org CTR20201073; ClinicalTrials.gov NCT04629846.
科研通智能强力驱动
Strongly Powered by AbleSci AI